



US008557285B2

(12) **United States Patent**
Plachetka

(10) **Patent No.:** **US 8,557,285 B2**

(45) **Date of Patent:** ***Oct. 15, 2013**

(54) **PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDS**

(75) Inventor: **John R. Plachetka**, Chapel Hill, NC (US)

(73) Assignee: **Pozen Inc.**, Chapel Hill, NC (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **13/215,855**

(22) Filed: **Aug. 23, 2011**

(65) **Prior Publication Data**

US 2012/0064156 A1 Mar. 15, 2012

Related U.S. Application Data

(60) Division of application No. 12/553,804, filed on Sep. 3, 2009, now abandoned, which is a division of application No. 11/129,320, filed on May 16, 2005, now Pat. No. 8,206,741, which is a continuation-in-part of application No. 10/158,216, filed on May 31, 2002, now Pat. No. 6,926,907.

(60) Provisional application No. 60/294,588, filed on Jun. 1, 2001.

(51) **Int. Cl.**

A61K 9/22 (2006.01)

A61K 9/32 (2006.01)

A61K 9/24 (2006.01)

A61K 9/52 (2006.01)

(52) **U.S. Cl.**

USPC **424/472**; 424/457; 424/463; 424/468; 424/474; 424/482

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,198,390 A 4/1980 Rider 424/471

4,255,431 A 3/1981 Junggren et al. 514/338

(Continued)

FOREIGN PATENT DOCUMENTS

AU 2006235929 11/2006

CA 2139653 7/2001

(Continued)

OTHER PUBLICATIONS

Goldstein et al., "PN400 significantly improves upper gastrointestinal tolerability compared with enteric-coated naproxen alone in patients requiring chronic NSAID therapy: Results from Two Prospective, Randomized, Controlled Trials," POZEN Inc. sponsored study, 2009. (Document D15 from Letter to European Patent Office for counterpart European Application No. 02 734 602.2, regarding Oral Proceedings dated Dec. 18, 2009).

(Continued)


Primary Examiner — Nissa Westerberg

(74) *Attorney, Agent, or Firm* — Parker Highlander PLLC

(57) **ABSTRACT**

The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.

4 Claims, 2 Drawing Sheets



(56)

References Cited

U.S. PATENT DOCUMENTS

4,344,929 A	8/1982	Bonsen et al.	424/466	6,632,451 B2	10/2003	Penhasi et al.	424/464
4,508,905 A	4/1985	Junggren et al.	546/273.7	6,641,838 B2	11/2003	Pather et al.	424/466
4,554,276 A	11/1985	LaMattina	514/272	6,645,988 B2	11/2003	Phillips	514/338
4,562,261 A	12/1985	Hirata et al.	548/184	6,673,819 B2	1/2004	Bergman et al.	514/338
4,619,934 A	10/1986	Sunshine et al.	514/277	6,685,964 B1	2/2004	Bartholomaeus et al.	424/489
4,676,984 A	6/1987	Wu et al.	424/689	6,699,885 B2	3/2004	Phillips	514/338
4,704,278 A	11/1987	Wu et al.	424/688	6,713,089 B1	3/2004	Bertelsen et al.	424/489
4,726,951 A	2/1988	Panoz et al.	424/465	6,749,867 B2	6/2004	Robinson et al.	424/489
4,738,974 A	4/1988	Brandstrom	514/338	6,780,882 B2	8/2004	Phillips	514/338
4,757,060 A	7/1988	Lukacsko et al.	514/160	6,787,164 B2	9/2004	Gelber et al.	424/729
4,758,579 A	7/1988	Kohl et al.	514/338	6,797,283 B1	9/2004	Edgren et al.	424/472
4,766,117 A	8/1988	Crawford et al.	514/219	6,869,615 B2	3/2005	Chen et al.	424/464
4,786,505 A	11/1988	Lovgren et al.	424/468	6,875,872 B1	4/2005	Lindberg et al.	
4,853,230 A	8/1989	Lovgren et al.	424/466	6,926,907 B2	8/2005	Plachetka	424/472
4,865,847 A	9/1989	Gosswein	424/439	7,029,701 B2	4/2006	Chen	424/489
4,948,581 A	8/1990	Sawayanagi et al.	424/497	7,030,162 B2	4/2006	Plachetka et al.	514/619
4,965,065 A	10/1990	Lukacsko et al.	514/162	7,060,694 B2	6/2006	Plachetka et al.	514/177
5,026,560 A	6/1991	Makino et al.	424/494	7,094,425 B2	8/2006	Scott et al.	424/451
5,035,899 A	7/1991	Saeki et al.	424/480	7,332,183 B2	2/2008	Plachetka et al.	424/472
5,037,815 A	8/1991	Lukacsko et al.	514/162	7,399,772 B2	7/2008	Phillips	514/338
5,043,358 A	8/1991	Lukacsko et al.	514/653	7,411,070 B2	8/2008	Cotton et al.	
5,051,262 A	9/1991	Panoz et al.	424/468	7,488,497 B2	2/2009	Depui et al.	424/472
5,093,132 A	3/1992	Makino et al.	424/475	7,745,466 B2	6/2010	Cotton et al.	
5,204,118 A	4/1993	Goldman et al.	424/489	7,785,626 B2	8/2010	Pettersson et al.	424/471
5,260,333 A	11/1993	Lukacsko et al.	514/471	7,846,914 B2	12/2010	Petrus	514/62
5,364,616 A	11/1994	Singer et al.	424/52	8,206,741 B2	6/2012	Plachetka et al.	
5,373,022 A	12/1994	Fawzi et al.	514/570	2001/0025107 A1	9/2001	Barberich et al.	546/273.7
5,409,709 A	4/1995	Ozawa et al.	424/464	2002/0012676 A1	1/2002	Lundberg et al.	424/468
5,417,980 A	5/1995	Goldman et al.	424/464	2002/0042433 A1	4/2002	Yelle et al.	514/100
5,466,436 A	11/1995	Stables	514/161	2002/0044962 A1	4/2002	Cherukuri et al.	424/426
5,514,663 A	5/1996	Mandel	514/33	2002/0045184 A1	4/2002	Chen	435/6.16
5,601,843 A	2/1997	Gimet	424/475	2002/0086029 A1	7/2002	Lundberg et al.	424/468
5,631,022 A	5/1997	Mandel et al.	424/456	2002/0090395 A1	7/2002	Woolfe et al.	424/400
5,643,960 A	7/1997	Breitner et al.	514/570	2002/0111370 A1	8/2002	Bergman et al.	514/338
5,667,802 A	9/1997	Grimberg	424/464	2002/0155153 A1	10/2002	Depui et al.	424/452
5,679,376 A	10/1997	Stevens et al.	424/472	2002/0160046 A1	10/2002	Robinson et al.	424/469
5,686,105 A	11/1997	Kelm et al.	424/452	2003/0008903 A1	1/2003	Barberich et al.	514/100
5,690,960 A	11/1997	Bengtsson et al.		2003/0040537 A1	2/2003	Plachetka et al.	514/406
5,702,723 A	12/1997	Griffin	424/463	2003/0113375 A1	6/2003	Lundberg et al.	424/468
5,714,504 A	2/1998	Lindberg et al.		2003/0129235 A1	7/2003	Chen et al.	424/470
5,716,648 A	2/1998	Halskov et al.	424/682	2003/0215527 A1	11/2003	Phillips	424/747
5,750,531 A	5/1998	Lee et al.	514/256	2003/0232080 A1	12/2003	Pather et al.	424/434
5,817,338 A	10/1998	Bergstrand et al.	424/468	2003/0232876 A1	12/2003	Plachetka	514/419
5,817,340 A	10/1998	Roche et al.	424/470	2004/0022846 A1	2/2004	Depui et al.	424/452
5,840,737 A	11/1998	Phillips	514/338	2004/0048896 A1	3/2004	Phillips	424/468
5,872,145 A	2/1999	Plachetka	514/415	2004/0121004 A1	6/2004	Taneja	424/464
5,877,192 A	3/1999	Lindberg et al.	514/338	2004/0131676 A1	7/2004	Taneja	424/468
5,900,424 A	5/1999	Kallstrom et al.		2004/0171646 A1	9/2004	Phillips	514/340
5,955,451 A	9/1999	Lichtenberger et al.	514/78	2004/0180089 A1	9/2004	Plachetka et al.	424/4
6,013,281 A	1/2000	Lundberg et al.	424/468	2005/0004171 A1	1/2005	Phillips	514/340
6,025,395 A	2/2000	Breitner et al.	514/570	2005/0042304 A1	2/2005	Phillips	424/747
6,060,499 A	5/2000	Plachetka	514/415	2005/0054682 A1	3/2005	Phillips	514/340
6,093,734 A	7/2000	Garst et al.	514/338	2005/0147668 A1	7/2005	Bertelsen et al.	424/489
6,132,768 A	10/2000	Sachs et al.	424/458	2005/0163847 A1	7/2005	Cheng et al.	424/464
6,132,771 A	10/2000	Depui et al.	424/468	2005/0227949 A1	10/2005	Edalatpour et al.	514/338
6,136,344 A	10/2000	Depui et al.	424/470	2005/0249806 A1	11/2005	Proehl et al.	514/338
6,160,020 A	12/2000	Ohannesian et al.	514/629	2005/0249811 A1	11/2005	Plachetka	424/472
6,162,816 A	12/2000	Bohlin et al.	210/95	2006/0165797 A1	7/2006	Plachetka	514/165
6,183,776 B1	2/2001	Depui et al.	424/468	2006/0177504 A1	8/2006	Sundharadas	424/488
6,183,779 B1	2/2001	Ouali et al.	424/472	2006/0178348 A1	8/2006	Plachetka	514/165
6,207,188 B1	3/2001	Gustavsson et al.	424/464	2006/0178349 A1	8/2006	Plachetka	514/165
6,231,888 B1	5/2001	Lerner et al.	424/463	2006/0287284 A1	12/2006	Schutze et al.	514/165
6,287,600 B1	9/2001	Ouali et al.	424/472	2007/0122470 A1	5/2007	Johansson et al.	424/451
6,365,184 B1	4/2002	Depui et al.	424/469	2007/0154542 A1	7/2007	Tananbaum et al.	424/457
6,369,085 B1	4/2002	Cotton et al.		2007/0184078 A1	8/2007	Chen	424/400
6,372,255 B1	4/2002	Saslowski	424/473	2007/0207200 A1	9/2007	Plachetka et al.	424/451
6,387,410 B1	5/2002	Woolfe	424/489	2007/0237820 A1	10/2007	Cheng et al.	424/474
6,395,298 B1	5/2002	Flannagan et al.	424/479	2007/0243251 A1	10/2007	Taneja	424/465
6,428,810 B1	8/2002	Bergstrand et al.	424/480	2008/0031941 A1	2/2008	Pettersson	424/463
6,485,747 B1	11/2002	Flanagan et al.	424/479	2008/0031950 A1	2/2008	Sesha	
6,489,346 B1	12/2002	Phillips	514/338	2008/0103169 A1	5/2008	Phillips	514/303
6,544,556 B1	4/2003	Chen et al.	424/469	2009/0074863 A1	3/2009	Taneja	424/465
6,599,529 B1	7/2003	Skinhoj et al.	424/458	2009/0075950 A1	3/2009	Taneja	
6,610,323 B1	8/2003	Lundberg et al.	424/458	2009/0297594 A1	12/2009	Depui et al.	424/451
6,613,354 B2	9/2003	Depui et al.	424/473	2010/0062064 A1	3/2010	Ault et al.	424/475
				2010/0172983 A1	7/2010	Plachetka	424/471
				2010/0178334 A1	7/2010	Johansson et al.	424/452
				2010/0330179 A1	12/2010	Ault et al.	424/472
				2012/0064156 A1	3/2012	Plachetka	

(56)

References Cited

OTHER PUBLICATIONS

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

DE	40 35 455	5/1992
DE	198 01 811	1/1998
EP	0 005 129	10/1979
EP	0 124 495	11/1984
EP	0 166 287	1/1986
EP	0 167 958	1/1986
EP	0 174 726	3/1986
EP	0 244 380	11/1987
EP	0 320 550	6/1989
EP	0 320 551	6/1989
EP	0 426 479	5/1991
EP	0 550 083	7/1993
EP	1 020 461	7/2000
EP	1 068 867	1/2001
EP	1 726 300	11/2006
EP	1 726 301	11/2006
EP	1 411 900	7/2010
GB	2 105 193	3/1983
GB	2 163 747	3/1986
GB	2 216 413	10/1989
JP	2005-145894	6/2005
WO	WO 85/03433	8/1985
WO	WO 90/06925	6/1990
WO	WO 91/16886	11/1991
WO	WO 91/16895	11/1991
WO	WO 91/16896	11/1991
WO	WO 93/11750	11/1991
WO	WO 91/19711	12/1991
WO	WO 91/19712	12/1991
WO	WO 93/12817	7/1993
WO	WO 94/07541	4/1994
WO	WO 94/27988	12/1994
WO	WO 95/01977	1/1995
WO	WO 95/32959	12/1995
WO	WO 96/05177	2/1996
WO	WO 96/05199	2/1996
WO	WO 96/14839	5/1996
WO	WO 96/22780	8/1996
WO	WO 97/11701	4/1997
WO	WO 97/25064	7/1997
WO	WO 98/13073	4/1998
WO	WO 98/22117	5/1998
WO	WO 98/22118	5/1998
WO	WO 98/54171	12/1998
WO	WO 99/00380	1/1999
WO	WO 99/12524	3/1999
WO	WO 99/29320	6/1999
WO	WO 99/66919	12/1999
WO	WO 00/01368	1/2000
WO	WO 00/15195	3/2000
WO	WO 00/59339	9/2000
WO	WO 00/71122	11/2000
WO	WO 00/72838	12/2000
WO	WO 00/78293	12/2000
WO	WO 01/66088	3/2001
WO	WO 01/24777	4/2001
WO	WO 02/22108	3/2002
WO	WO 02/066002	8/2002
WO	WO 02/098352	12/2002
WO	WO 03/017980	3/2003
WO	WO 2004/062552	7/2004
WO	WO 2004/064815	8/2004
WO	WO 2005/074536	8/2005
WO	WO 2005/074930	8/2005
WO	WO 2006/044202	4/2006
WO	WO 2007/064274	6/2007
WO	WO 2007/078874	7/2007
WO	WO 2008/101060	8/2008
WO	WO 2009/012393	1/2009
WO	WO 2009/145905	12/2009
WO	WO 2010/151697	12/2010

"A 12 month, phase 3, open-label, multi-center study to evaluate the long-term safety of PN 400," ClinicalTrials.gov, Sep. 11, 2007, accessed from <<http://clinicaltrials.gov/ct2/show/NCT00527904>> on Sep. 6, 2012.

"*Astrazeneca AB, Astrazeneca LP, KBI-E Inc., and Pozen, Inc. v Dr. Reddy's Laboratories Inc. and Dr. Reddy's Laboratories Ltd.: Dr. Reddy's Laboratories Inc. and Dr. Reddy's Laboratories Ltd.'s Invalidation contentions pursuant to L. Pat. R. 3.6(c)*," dated Nov. 23, 2011.

"*Astrazeneca AB, Astrazeneca LP, KBI-E Inc., and Pozen, Inc. v Lupin Ltd. and Lupin Pharmaceuticals, Inc.: Defendants Lupin Ltd. and Lupin Pharmaceuticals, Inc.'s Amended Invalidation Contentions Pursuant to L. PAT. R. 3.3 and 3.6(c)*," dated Apr. 20, 2012.

"*Astrazeneca AB, Astrazeneca LP, KBI-E Inc., and Pozen, Inc. v Lupin Ltd. and Lupin Pharmaceuticals, Inc.: Defendants Lupin Ltd. and Lupin Pharmaceuticals, Inc.'s Invalidation Contentions Pursuant to L. Pat. R. 3.3 and 3.6(c)*," dated Nov. 23, 2011.

"*Astrazeneca AB, Astrazeneca LP, KBI-E Inc., and Pozen, Inc. v Anchen Pharmaceuticals, Inc.: Anchen's Initial Invalidation Contentions*," dated May 11, 2012.

"*Astrazeneca AB, Astrazeneca LP, KBI-E Inc., and Pozen, Inc. v Dr. Reddy's Laboratories Inc. and Dr. Reddy's Laboratories Ltd.: Plaintiffs' Response to DRL's First Set of Interrogatories to Plaintiffs (Nos. 1-5)*," dated Mar. 5, 2012.

"Histamine H2 antagonist," accessed from <drugs.com> on Sep. 6, 2012.

"PK Study to evaluate esomeprazole plasma levels following the administration of PN 400," ClinicalTrials.gov, Jan. 11, 2008, accessed from, <<http://clinicaltrials.gov/ct2/show/NCT00599404>> on Sep. 6, 2012.

"Study evaluating the bioavailability of Naproxen 500 mg in three formulations," ClinicalTrials.gov, Apr. 23, 2008, accessed from, <<http://clinicaltrials.gov/ct2/show/NCT00665743>>, on Sep. 6, 2012.

Alexander et al., "Pilot evaluation of a novel combination table (PN 400) containing a proton pump inhibitor and a nonsteroidal anti-inflammatory drug in prevention of upper gastrointestinal mucosal injury," *American Journal of Gastroenterology*, 100(9), S68, 135, 2005.

Bergman et al., "Protection against aspirin-induced gastric lesions by lansoprazole: simultaneous evaluation of function and morphologic responses," *Clin Pharmacol Ther.*, 52(4): 413-416, 1992.

Goldstein et al., "116 A single table multilayer formulation of enteric-coated naproxen coupled with no-enteric-coated omeprazole is associated with a significantly reduced incidence of gastric ulcers vs. enteric-coated naproxen: A prospective, randomized double-blind study," 134(4), Supplement 1, A -19, 2008.

Hassan-Alin et al., "Lack of drug-drug interaction between esomeprazole and naproxen in healthy subjects," *Gastroenterology*, 124(4), Suppl.1, A541, 2003.

Jacques et al., "Final purification, enrichment, of partially resolved enantiomer mixtures," in *Enantiomers, Racemates, and Resolutions*, 423-434, 1981.

McKeage et al., "Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults," *Drugs*, 68(11):1571-15607, 2008.

Miner et al., "Clinical trial: evaluation of gastric acid suppression with three doses of immediate-release esomeprazole in the fixed-dose combination of PN 400 (naproxen/esomeprazole magnesium) compared with naproxen 500 mg and enteric-coated esomeprazole 20 mg: a randomized, open-label, Phase I study in healthy volunteers," *Aliment. Pharmacol. Ther.*, 32(3):414-424, 2010.

Miner et al., "T1969 Gastric acid suppression with PN400, a single-tablet, multilayer, fixed dose formulation combining an immediate-release esomeprazole layer and an enteric-coated (EC) naproxen core," *Gastroenterology*, 136(5), Suppl. 1, A-611, 2009.

Miner et al., "T1972 Pharmacokinetics of naproxen and esomeprazole in pn400, a single-tablet, multilayer formulation of enteric-coated naproxen coupled with immediate-release esomeprazole," *Gastroenterology*, 136(5), Suppl. 1, A-612, 2009.

(56)

References Cited

OTHER PUBLICATIONS

- Morgner et al., "Esomeprazole: prevention and treatment of NSAID-induced symptoms and ulcers," *Expert Opin Pharmacother.*, 8(7):975-988, 2007.
- Office Communication issued in European Patent Application 10177150.9, dated Nov. 12, 2010.
- Office Communication issued in European Patent Application No. 02734602.2, dated Feb. 22, 2010.
- Office Communication issued in European Patent Application No. 02734602.2, dated Apr. 29, 2010.
- Ramage et al., "Inhibition of food stimulated acid secretion by misoprostol, an orally active synthetic E1 analogue prostaglandin," *Br. J. Clin Pharmacol.*, 19:9-12, 1985.
- Scarpignato et al., "Towards a GI safer anti-inflammatory therapy," *Gastroenterology International*, 186-215, 1999.
- Takeuchi et al., "Effects of topical application of acidified omeprazole on acid secretion and transmucosal potential difference in anesthetized rat stomachs," *Japan J. Pharmacol.*, 47:397-1988.
- Weil et al., "Prophylactic aspirin and risk of peptic ulcer bleeding," *BMJ*, 310: 827-830, 1995.
- Wilson et al., "Effects of misoprostol on gastric acid and mucus secretion in man," *Digestive Diseases and Sciences*, 31(2): 126S-129S, 1986.
- Notice of Paragraph IV Certification Re: Dr. Reddy's Laboratories, Ltd.'s and Dr. Reddy's Laboratories, Inc.'s Naproxen and Esomeprazole Magnesium Delayed Release Tablets; U.S. Patent No. 6,926,907, from Dr. Reddy's Laboratories, Ltd./Dr. Reddy's Laboratories, Inc., dated Mar. 11, 2011.
- Abelo et al., "Pharmacodynamic modeling of reversible gastric acid pump inhibition in dog and man," *European Journal of Pharmaceutical Sciences*, 14:339-346, 2001.
- Andersson, "Pharmacokinetics, metabolism and interactions of acid pump inhibitors," *Clin. Pharmacokinet.*, 31(1):9-28, 1996.
- Approval of Amendments/correction filed May 10, 2010 dated Jun. 21, 2010 (application issued as EP 1 411 900 B1).
- Awtry et al., "Aspirin," *Circulation*, 101:1206-1218, 2000.
- Ballinger et al., "COX-2 inhibitors versus NSAIDs in gastrointestinal damage and prevention," *Exp. Opin. Pharmacother.*, 2(1):31-40, 2001.
- Barnett et al., "Effects of SCH 32651 on resting and stimulated acid secretion in guinea-pig isolated fundic mucosa," *Br. J. Pharmacol.*, 83:75-82, 1984.
- Berardi et al., "Elevation of gastric pH with ranitidine does not affect the release characteristics of sustained release ibuprofen tablets," *Biopharmaceutics & Drug Disposition*, 9:337-347, 1998.
- Bianchi Porro et al., "Pantoprazole versus placebo in prevention of NSAID-induced ulcers," *Gastroenterology*, 114(4):A74, 1998.
- Bianchi Porro et al., "Prevention of gastroduodenal damage with omeprazole in patients receiving continuous NSAIDs treatment. A double blind placebo controlled study," *Ital. J. Gastroenterol. Hepatol.*, 30:43-47, 1998.
- Bianchi Porro et al., "Why are non-steroidal anti-inflammatory drugs important in peptic ulcers?" *Aliment. Pharmacol. Therap.*, 1:540S-547S, 1987.
- Bigard et al., "Complete prevention by omeprazole of aspirin induced gastric lesions in healthy subjects," *Gut*, 29(5):A712, T49, 1988.
- Bigard et al., "Effet protecteur de l'omeprazole sur les lesions gastriques induites par une prise unique d'aspirine chez l'homme," *Gastroenterol. Clin. Biol.*, 12:770-771, 1998.
- Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," *N. Engl. J. Med.*, 343:1520-1528, 2000.
- Brown et al., "Aspirin- and indomethacin-induced ulcers and their antagonism by antihistamines," *Euro. J. Pharm.*, 51:275-283, 1978.
- Brown et al., "Prevention of the gastrointestinal adverse effects of nonsteroidal anti-inflammatory drugs," *Pract. Drug Safety*, 21:503-512, 1999.
- Byrn et al., "Pharmaceutical solids: A strategic approach to regulatory considerations," *Pharm. Res.*, 12(7): 945-954, 1995.
- Carrasco-Portugal et al., "Bioavailability of a formulation containing a diclofenac-ranitidine combination," *Proc. West. Pharmacol. Soc.*, 45:8-10, 2002.
- Chan et al., "Clopidogrel versus Aspirin and Esomeprazole to prevent recurrent ulcer bleeding," *New Eng. J. Med.*, 352:238-244, 2005.
- Chan et al., "Eradication of H. Pylori versus maintenance acid suppression to prevent recurrent ulcer hemorrhage in high risk NSAID users: A prospective randomized study," *Gastroenterology*, 114:A87, G0356, 1998.
- Chandramouli et al., "Prevention and management of NSAID-Induced gastropathy," *Journal of Pharmaceutical Pain and Symptom Control*, 8(4):27-40, 2000.
- Chang et al., "Polymethacrylates," *Handbook of Pharmaceutical Excipients*, Fifth Edition, Ed. Raymond C. Rowe, Paul J. Sheskey and Sian C. Owen, London: Pharmaceutical Press, 2006, pp. 553-560.
- Communication from the EPO regarding correction attempted for application 02 734 602.2, dated Apr. 29, 2010.
- Communication from the EPO regarding Grant of European patent for application 02 734 602.2, dated Feb. 2, 2010.
- Cullen et al., "Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users," *Aliment. Pharmacol. Ther.*, 12:135-140, 1998.
- Daneshmend et al., "Abolition by omeprazole of aspirin induced gastric mucosal injury in man," *Gut*, 31:514-517, 1990.
- Daneshmend et al., "Use of microbleeding and an ultrathin endoscope to assess gastric mucosal protection by famotidine," *Gastroenterology*, 97:944-9, 1989.
- Danjani, "Perspective on the gastric antisecretory effects of misoprostol in man," *Prostaglandins*, 33:68-77, 1987.
- Data sheet for "Arthrotec," 2009. (Document D8 from Letter to European Patent Office for counterpart European Application No. 02 734 602.2, regarding Oral Proceedings dated Dec. 18, 2009).
- Dent, "Why proton pump inhibition should heal and protect against nonsteroidal anti-inflammatory drug users," *Am. J. Med.*, 104:52S-55S, 1998.
- Ekstrom et al., "Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy," *Scand. J. Gastroenterol.*, 31:753-758, 1996.
- Ene et al., "A study of the inhibitory effects of SCH 28080 on gastric secretion in man," *Br. J. Pharmacol.*, 76:389-391, 1982.
- English translation of Bigard, et al., *Gastroenterol. Clin. Biol.*, 12:770-771, 1998.
- English translation of Muller et al, *Arzneimittel Forschung*, 47:758-460, 1997.
- English translation of Muller et al., *Arzneimittel-Forschung/Drug Res.*, 41(1):638-639, 1991.
- English translation of Simon et al., *Arzneimittel Forschung*, 45:701-703, 1995.
- Ensanullah et al., "Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine," *BMJ*, 297:1017-1021, 1998.
- Erlandsson et al., "Resolution of the enantiomers of omeprazole and some of its analogues by liquid chromatography on a triphenylcarbamoylcellulose-based stationary phase," *J. Chromatog.*, 532:305-319, 1990.
- European Search Report and Opinion issued in European application No. EP 09 17 8773, dated Feb. 11, 2010.
- European Search Report, issued in European Patent application No. EP 02734602.2, dated May 29, 2007.
- Feldman and Carlstedt, "Effect of antacid on absorption of enteric-coated aspirin," *JAMA*, 227(6):660-1, 1974.
- Florence and Jani, "Novel oral drug formulations their potential in modulating adverse effects," *Drug Safety*, 10(3):233-66, 1994.
- Frank et al., "Reduction of indomethacin induced gastroduodenal mucosal injury and gastrointestinal symptoms with cimetidine in normal subjects," *J. Rheum.*, 16:1249-1252, 1989.
- Gengo et al., "Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent isochemic events," *J. Clin. Pharmacol.*, 48:335-343, 2008.
- Gergmann et al., "Protection against aspirin-induced gastric lesions by lansoprazole: simultaneous evaluation of functional and morphologic responses," *Clin. Pharmacol. Ther.*, 52:413-416, 1992.

(56)

References Cited

OTHER PUBLICATIONS

- Goldstein et al., "PN400 significantly reduces the incidence of gastric ulcers compared with enteric-coated naproxen in patients requiring chronic NSAID therapy regardless of low-dose aspirin use: Results from two prospective, randomized controlled trials," POZEN Inc. sponsored study, 2009. (Document D16 from Letter to European Patent Office for counterpart European Application No. 02 734 602.2, regarding Oral Proceedings dated Dec. 18, 2009).
- Graham et al., "Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs," *Ann. Intern. Med.*, 119(4):257-262, 1993.
- Grosser et al., "Thromboxane generation," In *Platelets*, Alan Michelson Ed., pp. 565-574, Elsevier Science, 2007.
- Gurbel et al., "Abstract 4267; PA32520 (Single-tablet of enteric-coated aspirin 325 mg + Immediate-release Omeprazole 20 mg); Aspirin therapy combining greater thrombozyne suppression and lower upper gastrointestinal damage," *Circulation*, 118:S_855, 2008.
- Hart et al., "Aspirin dosage and thromboxane synthesis in patients with vascular disease," *Pharmacotherapy*, 23(9):579-584, 2003.
- Hawkey et al., "Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs," *N. Eng. J. Med.*, 338:727-734, 1998.
- Hawkey et al., "Prophylaxis of aspirin-induced gastric mucosal bleeding with ranitidine," *Aliment. Pharmacol. Therap.*, 2:245-252, 1988.
- Hawkey et al., "Strategies for preventing aspirin-induced gastric bleeding," *Scandinavian Journal of Gastroenterology*, vol. 21, Supplement 125, pp. 170-173, 1986.
- Hawkey, "Non-steroidal anti-inflammatory drug gastropathy: causes and treatment," *Scan. J. Gastroenterol.*, 31 Suppl. 220:124-7, 1996.
- Hawkey, "Progress in prophylaxis against nonsteroidal anti-inflammatory drug-associated ulcers and erosions," *Am. J. Med.*, 104:67S-74S, 1998.
- Hawkins et al., "The Gastrointestinal Toxicity of Nonsteroidal Anti-inflammatory Drugs. A Review of the Literature," *J. Pain and Symptom Management*, 20(2):140-151, 2000.
- Helander et al., "Structure and function of rat parietal cells during treatment with omeprazole, SCH 28080, SCH 32651, or ranitidine," *Scan. J. Gastroenterol.*, 25:799-809, 1990.
- Hogan et al., "Prescription of nonsteroidal anti-inflammatory drugs for elderly people in Alberta," *Can. Med. Assoc.*, 151(3):315-322, 1994.
- Howden, "Clinical pharmacology of omeprazole," *Clin. Pharmacokinet.*, 20:38-49, 1991.
- Ife et al., "Reversible inhibitors of the Gastric (H⁺/K⁺)-ATPase. 3. 3-Substituted-4-(phenylamino)quinolines," *J. med. Chem.*, 35:3413-3422, 1992.
- International Search Report issued in International application No. PCT/US02/17105, mailed Mar. 5, 2003.
- Jiranek et al., "Misoprostol reduces gastroduodenal injury from one week of aspirin: An endoscopic study," *Gastroenterology*, 96:656-661, 1989.
- Katz et al., "Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole," *Aliment. Pharmacol. Ther.*, 14:709-714, 2000.
- Keeling et al., "SK&F 96067 is a reversible, lumenally acting inhibitor of the gastric (H⁺+K⁺)-ATPase," *Biochemical Pharmacology*, 42(1):123-130, 1991.
- Kephart et al., "Coprescribing of nonsteroidal anti-inflammatory drugs and cytoprotective and antiulcer drugs in Nova Scotia's senior populations," *Clin. Ther.*, 17:1159-1173, 1995.
- Kimney et al., "Role of H₂-receptor blockers in the prevention of gastric injury resulting from nonsteroidal anti-inflammatory agents," *Am. J. Med.*, 84:49-52, 1988.
- Kitchingman et al., "Enhanced gastric mucosal bleeding with doses of aspirin used for prophylaxis and its reduction by ranitidine," *Br. J. Clin. Pharmacol.*, 28:581-585, 1989.
- Konturek et al., "Effects of omeprazole, a substituted benzimidazole, on gastrointestinal secretions, serum gastrin, and gastric mucosal blood flow in dogs," *Gastroenterology*, 86(1): 71-77, 1984.
- Lad et al., "Management of nonsteroidal anti-inflammatory drug-induced gastroduodenal disease by acid suppression," *Can. J. Gastroenterol.*, 13:135-142, 1999.
- Lana, "Prevention of aspirin-induced gastroduodenal damage: *H. pylori* infection eradication versus proton pump inhibitors or both," *Digestive and Liver Disease*, 36:655-657, 2004.
- Lanza et al., "A double-blind placebo-controlled comparison of the efficacy and safety of 50, 100, and 200 µg of misoprostol QID in the prevention of ibuprofen-induced gastric and duodenal mucosal lesions and symptoms," *Am. J. Gastroenterol.*, 84(6):633-636, 1989.
- Lanza et al., "Double-blinded, placebo-controlled endoscopic comparison of the mucosal protective effects of misoprostol versus cimetidine on tolmetin-induced injury to the stomach and duodenum," *Gastroenterology*, 95:289-294, 1988.
- Larsson et al., "Animal pharmacodynamics of omeprazole. A survey of its pharmacological properties in vivo," *Scand J Gastroenterol Suppl.*, 108:23-35, 1985.
- Lee et al., "Omeprazole prevents indomethacin-induced gastric ulcers in rabbits" *Aliment. Pharmacol. Ther.*, 10:571-576, 1996.
- Leese et al., "Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy Adults: A randomized, controlled trial," *J. Clin. Pharmacol.*, 40:124-132, 2000.
- Leonards and Levy, "Reduction or prevention of aspirin-induced occult gastrointestinal blood loss in man," *Clinical Pharmacology and Therapeutics*, 10(4):571-5, 1969.
- Letter to European Patent Office for counterpart European Application No. 02 734 602.2, regarding Oral Proceedings dated Dec. 18, 2009.
- Lichtenberger et al., "Nonsteroidal anti-inflammatory drug and phospholipid prodrugs: combination therapy with antisecretory agents in rats," *Gastroenterology*, 111:990-995, 1996.
- Lin and Lu, "Role of pharmacokinetics and metabolism in drug discovery and development," *Pharmacological Reviews*, 49(4):403-449, 1997.
- Maggi et al., "Press-coated tablets for the sequential pulsed administration of two different drugs," *Int. J. Pharm.*, 99:173-179, 1993.
- Mason and Winer, "Kinetics of aspirin, salicylic acid, and salicylic acid, and salicylic acid following oral administration of aspirin as a tablet and two buffered solutions," *Journal of Pharmaceutical Sciences*, 70(3):262-5, 1981.
- Mattsson et al., "Omeprazole provides protection against experimentally induced gastric mucosal lesions," *Eur. J. Pharmacol.*, 91:111-114, 1983.
- Morris et al., "Gastric cytoprotection is secondary to increased mucosal fluid secretion: A study of six cytoprotective agents in the rat," *J. Clin. Gastroenterol.*, 27(Suppl. 1):S53-63, 1998.
- Morrison et al., "The optimal analgesic dose of rofecoxib: overview of six randomized controlled trials," *JADA*, 131:1729-1737, 2000.
- Muller et al., "Untersuchungen zur schutzwirkung von lansoprazol auf die menschliche magenschleimhaut gegenüber niedrig dosierter acetylsalicylsäure," *Arzneimittel Forschung*, 47:758-760, 1997.
- Muller et al., "Verbesserung der gastroduodenalen verträglichkeit von azetylsalicylsäure durch ranitidine," *Arzneimittel-Forschung/Drug Res.*, 41(1):638-639, 1991.
- Naesdal et al., "Gastro-duodenal protection in an era of cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs," *European Journal of Gastroenterology & Hepatology*, 13(12):1401-1406, 2001.
- Nefesoglu et al., "Interaction of omeprazole with enteric-coated Salicylate tablets," *International Journal of Clinical Pharmacology and Therapeutics*, 36(10):549-553, 1998.
- Neuvonen and Kivisto, "Enhancement of drug absorption by antacids," *Clin. Pharmacokinet.*, 27(2):120-8, 1994.
- Notice of Opposition to a European Patent, submitted against European Patent application No. EP 1 411 900 on Apr. 15, 2011.
- Notice of Opposition to a European Patent, submitted against European Patent application No. EP 1 411 900 on Apr. 20, 2011.
- Oddsson et al., "Comparison between ranitidine and omeprazole for protection against gastroduodenal damage caused by naproxen," *Scand. J. Gastroenterol.*, 27:1045-1048, 1989.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.